雷莫芦单抗-话题@MedSci

#雷莫芦单抗#

3篇内容 | 1478人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2237596, encodeId=7dad223e5961c, content=<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a> <a href='/topic/show?id=65a2e7058ef' target=_blank style='color:#2F92EE;'>#紫杉醇#</a> <a href='/topic/show?id=ce279885039' target=_blank style='color:#2F92EE;'>#雷莫芦单抗#</a>, objectTitle=Lancet Oncol | 晚期胃癌治疗新突破：紫杉醇联合雷莫芦单抗，PFS 和 OS 双双获益（Ⅲ期ARMANI试验）, objectType=article, longId=851654, objectId=967585165430, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20241114/1731577202553_8538692.png, objectUrl=/article/show_article.do?id=967585165430, replyNumber=0, likeNumber=6, createdTime=2024-11-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=967585165430, moduleTitle=Lancet Oncol | 晚期胃癌治疗新突破：紫杉醇联合雷莫芦单抗，PFS 和 OS 双双获益（Ⅲ期ARMANI试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=967585165430)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2230325, encodeId=a9502230325f0, content=<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a> <a href='/topic/show?id=b0054454337' target=_blank style='color:#2F92EE;'>#奥希替尼#</a> <a href='/topic/show?id=ce279885039' target=_blank style='color:#2F92EE;'>#雷莫芦单抗#</a>, objectTitle=JCO | 延长生存期：RAMOSE 试验评估奥希替尼联合雷莫芦单抗治疗 EGFR 突变 NSCLC, objectType=article, longId=846489, objectId=d01b846489c9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240920/1726800373067_8538692.png, objectUrl=/article/show_article.do?id=d01b846489c9, replyNumber=0, likeNumber=44, createdTime=2024-10-11, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d01b846489c9, moduleTitle=JCO | 延长生存期：RAMOSE 试验评估奥希替尼联合雷莫芦单抗治疗 EGFR 突变 NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d01b846489c9)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2212072, encodeId=1a8422120e2be, content=<a href='/topic/show?id=ce279885039' target=_blank style='color:#2F92EE;'>#雷莫芦单抗#</a> <a href='/topic/show?id=34b54848271' target=_blank style='color:#2F92EE;'>#帕博利珠单抗#</a> <a href='/topic/show?id=690b11595e04' target=_blank style='color:#2F92EE;'>#头颈部鳞状细胞癌（HNSCC）#</a>, objectTitle=Lancet Oncol：雷莫芦单抗联合帕博利珠单抗治疗复发或转移性头颈鳞状细胞癌：一项单中心 I/II 期临床试验, objectType=article, longId=832088, objectId=4559832088ef, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240628/1719545059440_92910.png, objectUrl=/article/show_article.do?id=4559832088ef, replyNumber=0, likeNumber=114, createdTime=2024-06-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=4559832088ef, moduleTitle=Lancet Oncol：雷莫芦单抗联合帕博利珠单抗治疗复发或转移性头颈鳞状细胞癌：一项单中心 I/II 期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4559832088ef)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1241584, encodeId=401d124158482, content=<a href='/topic/show?id=ce279885039' target=_blank style='color:#2F92EE;'>#雷莫芦单抗#</a>+<a href='/topic/show?id=10dc3890e66' target=_blank style='color:#2F92EE;'>#吉西他滨#</a>作为二线疗法可显著延长恶性<a href='/topic/show?id=aa7f8421873' target=_blank style='color:#2F92EE;'>#胸膜间皮瘤#</a>患者的生存期, objectTitle=Lancet Oncol：雷莫芦单抗+吉西他滨作为二线疗法可显著延长恶性胸膜间皮瘤患者的生存期！, objectType=article, longId=216812, objectId=832d216812a4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202197/1631015730035_2110107.JPG, objectUrl=/article/show_article.do?id=832d216812a4, replyNumber=0, likeNumber=121, createdTime=2022-08-28, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=832d216812a4, moduleTitle=Lancet Oncol：雷莫芦单抗+吉西他滨作为二线疗法可显著延长恶性胸膜间皮瘤患者的生存期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=832d216812a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=919125, encodeId=2e4f91912578, content=<a href='/topic/show?id=ce279885039' target=_blank style='color:#2F92EE;'>#雷莫芦单抗#</a>, objectTitle=礼来雷莫芦单抗在中国递交上市申请，用于治疗胃癌, objectType=article, longId=206132, objectId=fe002061320d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021122/1611328767218_5295905.jpg, objectUrl=/article/show_article.do?id=fe002061320d, replyNumber=0, likeNumber=142, createdTime=2021-01-22, rootId=0, userName=zb1235672, userId=59321624668, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe002061320d, moduleTitle=礼来雷莫芦单抗在中国递交上市申请，用于治疗胃癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe002061320d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=601600, encodeId=675060160006, content=<a href='/topic/show?id=ce279885039' target=_blank style='color:#2F92EE;'>#雷莫芦单抗#</a>比贝伐更强一些, objectTitle=ASCO 2020 | 19.4个月！雷莫卢单抗联合厄洛替尼黑马亮相, objectType=article, longId=195229, objectId=29d0195229fb, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20200602/99899b22517f4bbabfdbe791f67bd49b.jpg, objectUrl=/article/show_article.do?id=29d0195229fb, replyNumber=0, likeNumber=0, createdTime=2020-06-06, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29d0195229fb, moduleTitle=ASCO 2020 | 19.4个月！雷莫卢单抗联合厄洛替尼黑马亮相, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29d0195229fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

雷莫芦单抗

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#胃癌# #紫杉醇# #雷莫芦单抗#

Lancet Oncol | 晚期胃癌治疗新突破：紫杉醇联合雷莫芦单抗，PFS 和 OS 双双获益（Ⅲ期ARMANI试验）

2024-11-18发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#NSCLC# #奥希替尼# #雷莫芦单抗#

JCO | 延长生存期：RAMOSE 试验评估奥希替尼联合雷莫芦单抗治疗 EGFR 突变 NSCLC

2024-10-11发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#雷莫芦单抗# #帕博利珠单抗# #头颈部鳞状细胞癌（HNSCC）#

Lancet Oncol：雷莫芦单抗联合帕博利珠单抗治疗复发或转移性头颈鳞状细胞癌：一项单中心 I/II 期临床试验

2024-06-28发表于上海

循证小兵 (审核中...)

前往app查看评论内容

#雷莫芦单抗#+#吉西他滨#作为二线疗法可显著延长恶性#胸膜间皮瘤#患者的生存期

Lancet Oncol：雷莫芦单抗+吉西他滨作为二线疗法可显著延长恶性胸膜间皮瘤患者的生存期！

2022-08-28

zb1235672 (审核中...)

前往app查看评论内容

#雷莫芦单抗#

礼来雷莫芦单抗在中国递交上市申请，用于治疗胃癌

2021-01-22

lovetcm (审核中...)

前往app查看评论内容

#雷莫芦单抗#比贝伐更强一些

ASCO 2020 | 19.4个月！雷莫卢单抗联合厄洛替尼黑马亮相

2020-06-06

科室
- - 订阅+
  - 更多科室
工具
服务